Review



nrf2 immunofluorescence staining  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    MedChemExpress nrf2 immunofluorescence staining
    MOTS-c mitigates hypoxia-mediated oxidative stress in placenta. (A) MDA content in placenta. (B) SOD activity in placenta. (C) <t>Nrf2</t> mRNA expression levels in placenta. (D) Representative western blotting images. (E) Total Nrf2 expression in placental tissues. (F) Nuclear Nrf2 expression in placental tissues. (G) Nrf2 expression in cytoplasm of placental tissues. (H) Representative immunofluorescence images and (I) quantification of Nrf2 in placenta. Scale bar, 50 μ m. (J) Relative mRNA expression levels of HO-1 and NQO-1. Data are expressed as the mean ± SD. Normal, n=6; IUGR, n=6; IUGR + MOTS-c, n=5. * P<0.05 vs. normal, ** P<0.01 vs. normal, *** P<0.001 vs. normal; # P<0.05 vs. IUGR; ## P<0.01 vs. IUGR; ### P<0.001 vs. IUGR. IUGR, intrauterine growth restriction; SOD, superoxide dismutase; MDA, malondialdehyde; Nrf2, nuclear factor erythroid 2-related factor 2; HO-1, heme oxygenase 1; NQO-1, NAD(P)H quinone dehydrogenase 1.
    Nrf2 Immunofluorescence Staining, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 85 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nrf2 immunofluorescence staining/product/MedChemExpress
    Average 95 stars, based on 85 article reviews
    nrf2 immunofluorescence staining - by Bioz Stars, 2026-02
    95/100 stars

    Images

    1) Product Images from "MOTS-c protects against placental injury via Nrf2 activation in hypoxia-induced intrauterine growth restriction mice"

    Article Title: MOTS-c protects against placental injury via Nrf2 activation in hypoxia-induced intrauterine growth restriction mice

    Journal: International Journal of Molecular Medicine

    doi: 10.3892/ijmm.2025.5697

    MOTS-c mitigates hypoxia-mediated oxidative stress in placenta. (A) MDA content in placenta. (B) SOD activity in placenta. (C) Nrf2 mRNA expression levels in placenta. (D) Representative western blotting images. (E) Total Nrf2 expression in placental tissues. (F) Nuclear Nrf2 expression in placental tissues. (G) Nrf2 expression in cytoplasm of placental tissues. (H) Representative immunofluorescence images and (I) quantification of Nrf2 in placenta. Scale bar, 50 μ m. (J) Relative mRNA expression levels of HO-1 and NQO-1. Data are expressed as the mean ± SD. Normal, n=6; IUGR, n=6; IUGR + MOTS-c, n=5. * P<0.05 vs. normal, ** P<0.01 vs. normal, *** P<0.001 vs. normal; # P<0.05 vs. IUGR; ## P<0.01 vs. IUGR; ### P<0.001 vs. IUGR. IUGR, intrauterine growth restriction; SOD, superoxide dismutase; MDA, malondialdehyde; Nrf2, nuclear factor erythroid 2-related factor 2; HO-1, heme oxygenase 1; NQO-1, NAD(P)H quinone dehydrogenase 1.
    Figure Legend Snippet: MOTS-c mitigates hypoxia-mediated oxidative stress in placenta. (A) MDA content in placenta. (B) SOD activity in placenta. (C) Nrf2 mRNA expression levels in placenta. (D) Representative western blotting images. (E) Total Nrf2 expression in placental tissues. (F) Nuclear Nrf2 expression in placental tissues. (G) Nrf2 expression in cytoplasm of placental tissues. (H) Representative immunofluorescence images and (I) quantification of Nrf2 in placenta. Scale bar, 50 μ m. (J) Relative mRNA expression levels of HO-1 and NQO-1. Data are expressed as the mean ± SD. Normal, n=6; IUGR, n=6; IUGR + MOTS-c, n=5. * P<0.05 vs. normal, ** P<0.01 vs. normal, *** P<0.001 vs. normal; # P<0.05 vs. IUGR; ## P<0.01 vs. IUGR; ### P<0.001 vs. IUGR. IUGR, intrauterine growth restriction; SOD, superoxide dismutase; MDA, malondialdehyde; Nrf2, nuclear factor erythroid 2-related factor 2; HO-1, heme oxygenase 1; NQO-1, NAD(P)H quinone dehydrogenase 1.

    Techniques Used: Activity Assay, Expressing, Western Blot, Immunofluorescence

    MOTS-c exposure attenuates oxidative stress in HUVECs. (A) Relative intensity of DCFH-DA staining. (B) Cellular SOD activity. (C) Cellular MDA content. (D) Representative images of MitoSOX staining. Scale bar, 10 μ m. (E) Representative images of JC-1 staining. Scale bar, 50 μ m. (F) Representative immunofluorescence images of Nrf2 in HUVECs. Scale bar, 5 μ m. (G) Relative nuclear to cytoplasm fluorescence ratio. Results are representative of three independent experiments. Data are expressed as the mean ± SD, n=4. *** P<0.001, # P<0.05 vs. PBS under hypoxic conditions, ## P<0.01 vs. PBS under hypoxic conditions; ### P<0.001 vs. PBS under hypoxic conditions. SOD, superoxide dismutase; MDA, malondialdehyde; DCFH-DA,2'7'-dichlorodihydro fluorescein diacetate ; Nrf2, nuclear factor erythroid 2-related factor 2.
    Figure Legend Snippet: MOTS-c exposure attenuates oxidative stress in HUVECs. (A) Relative intensity of DCFH-DA staining. (B) Cellular SOD activity. (C) Cellular MDA content. (D) Representative images of MitoSOX staining. Scale bar, 10 μ m. (E) Representative images of JC-1 staining. Scale bar, 50 μ m. (F) Representative immunofluorescence images of Nrf2 in HUVECs. Scale bar, 5 μ m. (G) Relative nuclear to cytoplasm fluorescence ratio. Results are representative of three independent experiments. Data are expressed as the mean ± SD, n=4. *** P<0.001, # P<0.05 vs. PBS under hypoxic conditions, ## P<0.01 vs. PBS under hypoxic conditions; ### P<0.001 vs. PBS under hypoxic conditions. SOD, superoxide dismutase; MDA, malondialdehyde; DCFH-DA,2'7'-dichlorodihydro fluorescein diacetate ; Nrf2, nuclear factor erythroid 2-related factor 2.

    Techniques Used: Staining, Activity Assay, Immunofluorescence, Fluorescence

    Nrf2 inhibitor ML385 offset the protective effect of MOTS-c against hypoxia-induced dysregulated angiogenesis and oxidative stress in HUVECs. (A) Representative images and (B) quantitative analysis of the in vitro tube formation. Scale bar, 10 μ m. (C) Representative images of DCFH-DA staining and (D) quantification of cellular ROS. Scale bar, 50 μ m. Results are representative of three independent experiments. Data are expressed as the mean ± SD. * P<0.05, ** P<0.01. NS, not significant; DCFH-DA,2',7'-dichlorodihydro fluorescein diacetate; Nrf2, nuclear factor erythroid 2-related factor 2.
    Figure Legend Snippet: Nrf2 inhibitor ML385 offset the protective effect of MOTS-c against hypoxia-induced dysregulated angiogenesis and oxidative stress in HUVECs. (A) Representative images and (B) quantitative analysis of the in vitro tube formation. Scale bar, 10 μ m. (C) Representative images of DCFH-DA staining and (D) quantification of cellular ROS. Scale bar, 50 μ m. Results are representative of three independent experiments. Data are expressed as the mean ± SD. * P<0.05, ** P<0.01. NS, not significant; DCFH-DA,2',7'-dichlorodihydro fluorescein diacetate; Nrf2, nuclear factor erythroid 2-related factor 2.

    Techniques Used: In Vitro, Staining

    Nrf2 overexpression does not enhance the beneficial effects of MOTS-c on hypoxia-stimulated HUVECs. (A) Relative Nrf2 mRNA expression levels. (B) Cell viability. (C). Representative images of DCFH-DA staining and (D) quantification of cellular ROS. Scale bar, 10 μ m. Data are expressed as the mean ± SD. * P<0.05, ** P<0.01, *** P<0.001, # P<0.05, ## P<0.01. NS, not significant; Nrf2, nuclear factor erythroid 2-related factor 2; ROS, reactive oxygen species; OE, overexpression; DCFH-DA, 2',7'-dichlorodihydro fluorescein diacetate.
    Figure Legend Snippet: Nrf2 overexpression does not enhance the beneficial effects of MOTS-c on hypoxia-stimulated HUVECs. (A) Relative Nrf2 mRNA expression levels. (B) Cell viability. (C). Representative images of DCFH-DA staining and (D) quantification of cellular ROS. Scale bar, 10 μ m. Data are expressed as the mean ± SD. * P<0.05, ** P<0.01, *** P<0.001, # P<0.05, ## P<0.01. NS, not significant; Nrf2, nuclear factor erythroid 2-related factor 2; ROS, reactive oxygen species; OE, overexpression; DCFH-DA, 2',7'-dichlorodihydro fluorescein diacetate.

    Techniques Used: Over Expression, Expressing, Staining

    MOTS-c protects against hypoxia-induced placental insufficiency in an Nrf2-dependent manner. (A) Morphology of fetal mice on GD17.5 in WT and Nrf2 KO mice. (B) Placental efficiency, which represents the ratio of fetal to placenta weight. (C) Representative images of H&E staining of placental tissues. Scale bar, 100 μ m. (D) Quantification of the placental blood sinus area. (E) Western blotting analysis of CD31, VEGFA and VEGFR2 protein expression levels in placenta. (F) Relative mRNA expression levels of Pgf , Igf2 , Glut1 , Fatp4 and Snat2 in placenta. Data are expressed as mean ± SD. n=4-6. * P<0.05 vs. normal, ** P<0.01 vs. normal, *** P<0.001 vs. normal, # P<0.05 vs. IUGR, ### P<0.001 vs. IUGR.. NS, not significant; IUGR, intrauterine growth restriction; GD, gestational day; Pgf, placental growth factor; Nrf2, nuclear factor erythroid 2-related factor 2; Igf2, insulin-like growth factor 2; Glut1, glucose transporter type 1; Fatp4, fatty acid transporter 4; Snat2, sodium-dependent neutral amino acid transporter-2; VEGFA, vascular endothelial growth factor A; VEGFR2, VEGF receptor 2.
    Figure Legend Snippet: MOTS-c protects against hypoxia-induced placental insufficiency in an Nrf2-dependent manner. (A) Morphology of fetal mice on GD17.5 in WT and Nrf2 KO mice. (B) Placental efficiency, which represents the ratio of fetal to placenta weight. (C) Representative images of H&E staining of placental tissues. Scale bar, 100 μ m. (D) Quantification of the placental blood sinus area. (E) Western blotting analysis of CD31, VEGFA and VEGFR2 protein expression levels in placenta. (F) Relative mRNA expression levels of Pgf , Igf2 , Glut1 , Fatp4 and Snat2 in placenta. Data are expressed as mean ± SD. n=4-6. * P<0.05 vs. normal, ** P<0.01 vs. normal, *** P<0.001 vs. normal, # P<0.05 vs. IUGR, ### P<0.001 vs. IUGR.. NS, not significant; IUGR, intrauterine growth restriction; GD, gestational day; Pgf, placental growth factor; Nrf2, nuclear factor erythroid 2-related factor 2; Igf2, insulin-like growth factor 2; Glut1, glucose transporter type 1; Fatp4, fatty acid transporter 4; Snat2, sodium-dependent neutral amino acid transporter-2; VEGFA, vascular endothelial growth factor A; VEGFR2, VEGF receptor 2.

    Techniques Used: Staining, Western Blot, Expressing



    Similar Products

    95
    MedChemExpress nrf2 immunofluorescence staining
    MOTS-c mitigates hypoxia-mediated oxidative stress in placenta. (A) MDA content in placenta. (B) SOD activity in placenta. (C) <t>Nrf2</t> mRNA expression levels in placenta. (D) Representative western blotting images. (E) Total Nrf2 expression in placental tissues. (F) Nuclear Nrf2 expression in placental tissues. (G) Nrf2 expression in cytoplasm of placental tissues. (H) Representative immunofluorescence images and (I) quantification of Nrf2 in placenta. Scale bar, 50 μ m. (J) Relative mRNA expression levels of HO-1 and NQO-1. Data are expressed as the mean ± SD. Normal, n=6; IUGR, n=6; IUGR + MOTS-c, n=5. * P<0.05 vs. normal, ** P<0.01 vs. normal, *** P<0.001 vs. normal; # P<0.05 vs. IUGR; ## P<0.01 vs. IUGR; ### P<0.001 vs. IUGR. IUGR, intrauterine growth restriction; SOD, superoxide dismutase; MDA, malondialdehyde; Nrf2, nuclear factor erythroid 2-related factor 2; HO-1, heme oxygenase 1; NQO-1, NAD(P)H quinone dehydrogenase 1.
    Nrf2 Immunofluorescence Staining, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nrf2 immunofluorescence staining/product/MedChemExpress
    Average 95 stars, based on 1 article reviews
    nrf2 immunofluorescence staining - by Bioz Stars, 2026-02
    95/100 stars
      Buy from Supplier

    99
    Proteintech immunofluorescence staining
    MOTS-c mitigates hypoxia-mediated oxidative stress in placenta. (A) MDA content in placenta. (B) SOD activity in placenta. (C) <t>Nrf2</t> mRNA expression levels in placenta. (D) Representative western blotting images. (E) Total Nrf2 expression in placental tissues. (F) Nuclear Nrf2 expression in placental tissues. (G) Nrf2 expression in cytoplasm of placental tissues. (H) Representative immunofluorescence images and (I) quantification of Nrf2 in placenta. Scale bar, 50 μ m. (J) Relative mRNA expression levels of HO-1 and NQO-1. Data are expressed as the mean ± SD. Normal, n=6; IUGR, n=6; IUGR + MOTS-c, n=5. * P<0.05 vs. normal, ** P<0.01 vs. normal, *** P<0.001 vs. normal; # P<0.05 vs. IUGR; ## P<0.01 vs. IUGR; ### P<0.001 vs. IUGR. IUGR, intrauterine growth restriction; SOD, superoxide dismutase; MDA, malondialdehyde; Nrf2, nuclear factor erythroid 2-related factor 2; HO-1, heme oxygenase 1; NQO-1, NAD(P)H quinone dehydrogenase 1.
    Immunofluorescence Staining, supplied by Proteintech, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/immunofluorescence staining/product/Proteintech
    Average 99 stars, based on 1 article reviews
    immunofluorescence staining - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    98
    Proteintech nrf2 nuclear immunofluorescence staining in vitro
    MOTS-c mitigates hypoxia-mediated oxidative stress in placenta. (A) MDA content in placenta. (B) SOD activity in placenta. (C) <t>Nrf2</t> mRNA expression levels in placenta. (D) Representative western blotting images. (E) Total Nrf2 expression in placental tissues. (F) Nuclear Nrf2 expression in placental tissues. (G) Nrf2 expression in cytoplasm of placental tissues. (H) Representative immunofluorescence images and (I) quantification of Nrf2 in placenta. Scale bar, 50 μ m. (J) Relative mRNA expression levels of HO-1 and NQO-1. Data are expressed as the mean ± SD. Normal, n=6; IUGR, n=6; IUGR + MOTS-c, n=5. * P<0.05 vs. normal, ** P<0.01 vs. normal, *** P<0.001 vs. normal; # P<0.05 vs. IUGR; ## P<0.01 vs. IUGR; ### P<0.001 vs. IUGR. IUGR, intrauterine growth restriction; SOD, superoxide dismutase; MDA, malondialdehyde; Nrf2, nuclear factor erythroid 2-related factor 2; HO-1, heme oxygenase 1; NQO-1, NAD(P)H quinone dehydrogenase 1.
    Nrf2 Nuclear Immunofluorescence Staining In Vitro, supplied by Proteintech, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nrf2 nuclear immunofluorescence staining in vitro/product/Proteintech
    Average 98 stars, based on 1 article reviews
    nrf2 nuclear immunofluorescence staining in vitro - by Bioz Stars, 2026-02
    98/100 stars
      Buy from Supplier

    90
    MitoQ Ltd immunofluorescence staining of nrf2
    MitoQ accelerated translocation of <t>Nrf2</t> from cytoplasm to nucleus. A-C. The levels of nuclear Nrf2, cytoplasmic Nrf2, and total Nrf2 were measured by western blot. D, E. The ratios of nuclear Nrf2 and cytoplasmic Nrf2. F. Representative immunofluorescence staining of Nrf2 after MitoQ treatment in mice with TBI. Double immunofluorescence analysis was performed with Nrf2 antibodies (red), NeuN (green), and DAPI (blue). The merged immunofluorescent images with NeuN, Nrf2 and DAPI represented for Nrf2 translocation from the cytoplasm to the nucleus. The white arrows indicate expressions and overlaps of NeuN, Nrf2 and DAPI. Scale bar =50 μm; Data are presented as mean ± SEM (n=6). * P < 0.05, ** P < 0.01 and *** P < 0.001 vs. sham group; ns P > 0.05 vs. TBI group; # P < 0.05 and ## P < 0.01 vs. vehicle-treated group.
    Immunofluorescence Staining Of Nrf2, supplied by MitoQ Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/immunofluorescence staining of nrf2/product/MitoQ Ltd
    Average 90 stars, based on 1 article reviews
    immunofluorescence staining of nrf2 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    98
    Santa Cruz Biotechnology immunofluorescent staining with anti nrf2
    MitoQ accelerated translocation of <t>Nrf2</t> from cytoplasm to nucleus. A-C. The levels of nuclear Nrf2, cytoplasmic Nrf2, and total Nrf2 were measured by western blot. D, E. The ratios of nuclear Nrf2 and cytoplasmic Nrf2. F. Representative immunofluorescence staining of Nrf2 after MitoQ treatment in mice with TBI. Double immunofluorescence analysis was performed with Nrf2 antibodies (red), NeuN (green), and DAPI (blue). The merged immunofluorescent images with NeuN, Nrf2 and DAPI represented for Nrf2 translocation from the cytoplasm to the nucleus. The white arrows indicate expressions and overlaps of NeuN, Nrf2 and DAPI. Scale bar =50 μm; Data are presented as mean ± SEM (n=6). * P < 0.05, ** P < 0.01 and *** P < 0.001 vs. sham group; ns P > 0.05 vs. TBI group; # P < 0.05 and ## P < 0.01 vs. vehicle-treated group.
    Immunofluorescent Staining With Anti Nrf2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/immunofluorescent staining with anti nrf2/product/Santa Cruz Biotechnology
    Average 98 stars, based on 1 article reviews
    immunofluorescent staining with anti nrf2 - by Bioz Stars, 2026-02
    98/100 stars
      Buy from Supplier

    90
    Santa Cruz Biotechnology immunofluorescent staining against nrf2
    MitoQ accelerated translocation of <t>Nrf2</t> from cytoplasm to nucleus. A-C. The levels of nuclear Nrf2, cytoplasmic Nrf2, and total Nrf2 were measured by western blot. D, E. The ratios of nuclear Nrf2 and cytoplasmic Nrf2. F. Representative immunofluorescence staining of Nrf2 after MitoQ treatment in mice with TBI. Double immunofluorescence analysis was performed with Nrf2 antibodies (red), NeuN (green), and DAPI (blue). The merged immunofluorescent images with NeuN, Nrf2 and DAPI represented for Nrf2 translocation from the cytoplasm to the nucleus. The white arrows indicate expressions and overlaps of NeuN, Nrf2 and DAPI. Scale bar =50 μm; Data are presented as mean ± SEM (n=6). * P < 0.05, ** P < 0.01 and *** P < 0.001 vs. sham group; ns P > 0.05 vs. TBI group; # P < 0.05 and ## P < 0.01 vs. vehicle-treated group.
    Immunofluorescent Staining Against Nrf2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/immunofluorescent staining against nrf2/product/Santa Cruz Biotechnology
    Average 90 stars, based on 1 article reviews
    immunofluorescent staining against nrf2 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    Image Search Results


    MOTS-c mitigates hypoxia-mediated oxidative stress in placenta. (A) MDA content in placenta. (B) SOD activity in placenta. (C) Nrf2 mRNA expression levels in placenta. (D) Representative western blotting images. (E) Total Nrf2 expression in placental tissues. (F) Nuclear Nrf2 expression in placental tissues. (G) Nrf2 expression in cytoplasm of placental tissues. (H) Representative immunofluorescence images and (I) quantification of Nrf2 in placenta. Scale bar, 50 μ m. (J) Relative mRNA expression levels of HO-1 and NQO-1. Data are expressed as the mean ± SD. Normal, n=6; IUGR, n=6; IUGR + MOTS-c, n=5. * P<0.05 vs. normal, ** P<0.01 vs. normal, *** P<0.001 vs. normal; # P<0.05 vs. IUGR; ## P<0.01 vs. IUGR; ### P<0.001 vs. IUGR. IUGR, intrauterine growth restriction; SOD, superoxide dismutase; MDA, malondialdehyde; Nrf2, nuclear factor erythroid 2-related factor 2; HO-1, heme oxygenase 1; NQO-1, NAD(P)H quinone dehydrogenase 1.

    Journal: International Journal of Molecular Medicine

    Article Title: MOTS-c protects against placental injury via Nrf2 activation in hypoxia-induced intrauterine growth restriction mice

    doi: 10.3892/ijmm.2025.5697

    Figure Lengend Snippet: MOTS-c mitigates hypoxia-mediated oxidative stress in placenta. (A) MDA content in placenta. (B) SOD activity in placenta. (C) Nrf2 mRNA expression levels in placenta. (D) Representative western blotting images. (E) Total Nrf2 expression in placental tissues. (F) Nuclear Nrf2 expression in placental tissues. (G) Nrf2 expression in cytoplasm of placental tissues. (H) Representative immunofluorescence images and (I) quantification of Nrf2 in placenta. Scale bar, 50 μ m. (J) Relative mRNA expression levels of HO-1 and NQO-1. Data are expressed as the mean ± SD. Normal, n=6; IUGR, n=6; IUGR + MOTS-c, n=5. * P<0.05 vs. normal, ** P<0.01 vs. normal, *** P<0.001 vs. normal; # P<0.05 vs. IUGR; ## P<0.01 vs. IUGR; ### P<0.001 vs. IUGR. IUGR, intrauterine growth restriction; SOD, superoxide dismutase; MDA, malondialdehyde; Nrf2, nuclear factor erythroid 2-related factor 2; HO-1, heme oxygenase 1; NQO-1, NAD(P)H quinone dehydrogenase 1.

    Article Snippet: For Nrf2 immunofluorescence staining in HUVECs, cells were fixed with 100% methanol for 15 min at −20°C, followed by permeabilization with 0.1% Triton X-100 for 10 min and blocked with 1% bovine serum albumin (BSA) (cat. no. HY-D0842; MedChemExpress) for 60 min at room temperature.

    Techniques: Activity Assay, Expressing, Western Blot, Immunofluorescence

    MOTS-c exposure attenuates oxidative stress in HUVECs. (A) Relative intensity of DCFH-DA staining. (B) Cellular SOD activity. (C) Cellular MDA content. (D) Representative images of MitoSOX staining. Scale bar, 10 μ m. (E) Representative images of JC-1 staining. Scale bar, 50 μ m. (F) Representative immunofluorescence images of Nrf2 in HUVECs. Scale bar, 5 μ m. (G) Relative nuclear to cytoplasm fluorescence ratio. Results are representative of three independent experiments. Data are expressed as the mean ± SD, n=4. *** P<0.001, # P<0.05 vs. PBS under hypoxic conditions, ## P<0.01 vs. PBS under hypoxic conditions; ### P<0.001 vs. PBS under hypoxic conditions. SOD, superoxide dismutase; MDA, malondialdehyde; DCFH-DA,2'7'-dichlorodihydro fluorescein diacetate ; Nrf2, nuclear factor erythroid 2-related factor 2.

    Journal: International Journal of Molecular Medicine

    Article Title: MOTS-c protects against placental injury via Nrf2 activation in hypoxia-induced intrauterine growth restriction mice

    doi: 10.3892/ijmm.2025.5697

    Figure Lengend Snippet: MOTS-c exposure attenuates oxidative stress in HUVECs. (A) Relative intensity of DCFH-DA staining. (B) Cellular SOD activity. (C) Cellular MDA content. (D) Representative images of MitoSOX staining. Scale bar, 10 μ m. (E) Representative images of JC-1 staining. Scale bar, 50 μ m. (F) Representative immunofluorescence images of Nrf2 in HUVECs. Scale bar, 5 μ m. (G) Relative nuclear to cytoplasm fluorescence ratio. Results are representative of three independent experiments. Data are expressed as the mean ± SD, n=4. *** P<0.001, # P<0.05 vs. PBS under hypoxic conditions, ## P<0.01 vs. PBS under hypoxic conditions; ### P<0.001 vs. PBS under hypoxic conditions. SOD, superoxide dismutase; MDA, malondialdehyde; DCFH-DA,2'7'-dichlorodihydro fluorescein diacetate ; Nrf2, nuclear factor erythroid 2-related factor 2.

    Article Snippet: For Nrf2 immunofluorescence staining in HUVECs, cells were fixed with 100% methanol for 15 min at −20°C, followed by permeabilization with 0.1% Triton X-100 for 10 min and blocked with 1% bovine serum albumin (BSA) (cat. no. HY-D0842; MedChemExpress) for 60 min at room temperature.

    Techniques: Staining, Activity Assay, Immunofluorescence, Fluorescence

    Nrf2 inhibitor ML385 offset the protective effect of MOTS-c against hypoxia-induced dysregulated angiogenesis and oxidative stress in HUVECs. (A) Representative images and (B) quantitative analysis of the in vitro tube formation. Scale bar, 10 μ m. (C) Representative images of DCFH-DA staining and (D) quantification of cellular ROS. Scale bar, 50 μ m. Results are representative of three independent experiments. Data are expressed as the mean ± SD. * P<0.05, ** P<0.01. NS, not significant; DCFH-DA,2',7'-dichlorodihydro fluorescein diacetate; Nrf2, nuclear factor erythroid 2-related factor 2.

    Journal: International Journal of Molecular Medicine

    Article Title: MOTS-c protects against placental injury via Nrf2 activation in hypoxia-induced intrauterine growth restriction mice

    doi: 10.3892/ijmm.2025.5697

    Figure Lengend Snippet: Nrf2 inhibitor ML385 offset the protective effect of MOTS-c against hypoxia-induced dysregulated angiogenesis and oxidative stress in HUVECs. (A) Representative images and (B) quantitative analysis of the in vitro tube formation. Scale bar, 10 μ m. (C) Representative images of DCFH-DA staining and (D) quantification of cellular ROS. Scale bar, 50 μ m. Results are representative of three independent experiments. Data are expressed as the mean ± SD. * P<0.05, ** P<0.01. NS, not significant; DCFH-DA,2',7'-dichlorodihydro fluorescein diacetate; Nrf2, nuclear factor erythroid 2-related factor 2.

    Article Snippet: For Nrf2 immunofluorescence staining in HUVECs, cells were fixed with 100% methanol for 15 min at −20°C, followed by permeabilization with 0.1% Triton X-100 for 10 min and blocked with 1% bovine serum albumin (BSA) (cat. no. HY-D0842; MedChemExpress) for 60 min at room temperature.

    Techniques: In Vitro, Staining

    Nrf2 overexpression does not enhance the beneficial effects of MOTS-c on hypoxia-stimulated HUVECs. (A) Relative Nrf2 mRNA expression levels. (B) Cell viability. (C). Representative images of DCFH-DA staining and (D) quantification of cellular ROS. Scale bar, 10 μ m. Data are expressed as the mean ± SD. * P<0.05, ** P<0.01, *** P<0.001, # P<0.05, ## P<0.01. NS, not significant; Nrf2, nuclear factor erythroid 2-related factor 2; ROS, reactive oxygen species; OE, overexpression; DCFH-DA, 2',7'-dichlorodihydro fluorescein diacetate.

    Journal: International Journal of Molecular Medicine

    Article Title: MOTS-c protects against placental injury via Nrf2 activation in hypoxia-induced intrauterine growth restriction mice

    doi: 10.3892/ijmm.2025.5697

    Figure Lengend Snippet: Nrf2 overexpression does not enhance the beneficial effects of MOTS-c on hypoxia-stimulated HUVECs. (A) Relative Nrf2 mRNA expression levels. (B) Cell viability. (C). Representative images of DCFH-DA staining and (D) quantification of cellular ROS. Scale bar, 10 μ m. Data are expressed as the mean ± SD. * P<0.05, ** P<0.01, *** P<0.001, # P<0.05, ## P<0.01. NS, not significant; Nrf2, nuclear factor erythroid 2-related factor 2; ROS, reactive oxygen species; OE, overexpression; DCFH-DA, 2',7'-dichlorodihydro fluorescein diacetate.

    Article Snippet: For Nrf2 immunofluorescence staining in HUVECs, cells were fixed with 100% methanol for 15 min at −20°C, followed by permeabilization with 0.1% Triton X-100 for 10 min and blocked with 1% bovine serum albumin (BSA) (cat. no. HY-D0842; MedChemExpress) for 60 min at room temperature.

    Techniques: Over Expression, Expressing, Staining

    MOTS-c protects against hypoxia-induced placental insufficiency in an Nrf2-dependent manner. (A) Morphology of fetal mice on GD17.5 in WT and Nrf2 KO mice. (B) Placental efficiency, which represents the ratio of fetal to placenta weight. (C) Representative images of H&E staining of placental tissues. Scale bar, 100 μ m. (D) Quantification of the placental blood sinus area. (E) Western blotting analysis of CD31, VEGFA and VEGFR2 protein expression levels in placenta. (F) Relative mRNA expression levels of Pgf , Igf2 , Glut1 , Fatp4 and Snat2 in placenta. Data are expressed as mean ± SD. n=4-6. * P<0.05 vs. normal, ** P<0.01 vs. normal, *** P<0.001 vs. normal, # P<0.05 vs. IUGR, ### P<0.001 vs. IUGR.. NS, not significant; IUGR, intrauterine growth restriction; GD, gestational day; Pgf, placental growth factor; Nrf2, nuclear factor erythroid 2-related factor 2; Igf2, insulin-like growth factor 2; Glut1, glucose transporter type 1; Fatp4, fatty acid transporter 4; Snat2, sodium-dependent neutral amino acid transporter-2; VEGFA, vascular endothelial growth factor A; VEGFR2, VEGF receptor 2.

    Journal: International Journal of Molecular Medicine

    Article Title: MOTS-c protects against placental injury via Nrf2 activation in hypoxia-induced intrauterine growth restriction mice

    doi: 10.3892/ijmm.2025.5697

    Figure Lengend Snippet: MOTS-c protects against hypoxia-induced placental insufficiency in an Nrf2-dependent manner. (A) Morphology of fetal mice on GD17.5 in WT and Nrf2 KO mice. (B) Placental efficiency, which represents the ratio of fetal to placenta weight. (C) Representative images of H&E staining of placental tissues. Scale bar, 100 μ m. (D) Quantification of the placental blood sinus area. (E) Western blotting analysis of CD31, VEGFA and VEGFR2 protein expression levels in placenta. (F) Relative mRNA expression levels of Pgf , Igf2 , Glut1 , Fatp4 and Snat2 in placenta. Data are expressed as mean ± SD. n=4-6. * P<0.05 vs. normal, ** P<0.01 vs. normal, *** P<0.001 vs. normal, # P<0.05 vs. IUGR, ### P<0.001 vs. IUGR.. NS, not significant; IUGR, intrauterine growth restriction; GD, gestational day; Pgf, placental growth factor; Nrf2, nuclear factor erythroid 2-related factor 2; Igf2, insulin-like growth factor 2; Glut1, glucose transporter type 1; Fatp4, fatty acid transporter 4; Snat2, sodium-dependent neutral amino acid transporter-2; VEGFA, vascular endothelial growth factor A; VEGFR2, VEGF receptor 2.

    Article Snippet: For Nrf2 immunofluorescence staining in HUVECs, cells were fixed with 100% methanol for 15 min at −20°C, followed by permeabilization with 0.1% Triton X-100 for 10 min and blocked with 1% bovine serum albumin (BSA) (cat. no. HY-D0842; MedChemExpress) for 60 min at room temperature.

    Techniques: Staining, Western Blot, Expressing

    MitoQ accelerated translocation of Nrf2 from cytoplasm to nucleus. A-C. The levels of nuclear Nrf2, cytoplasmic Nrf2, and total Nrf2 were measured by western blot. D, E. The ratios of nuclear Nrf2 and cytoplasmic Nrf2. F. Representative immunofluorescence staining of Nrf2 after MitoQ treatment in mice with TBI. Double immunofluorescence analysis was performed with Nrf2 antibodies (red), NeuN (green), and DAPI (blue). The merged immunofluorescent images with NeuN, Nrf2 and DAPI represented for Nrf2 translocation from the cytoplasm to the nucleus. The white arrows indicate expressions and overlaps of NeuN, Nrf2 and DAPI. Scale bar =50 μm; Data are presented as mean ± SEM (n=6). * P < 0.05, ** P < 0.01 and *** P < 0.001 vs. sham group; ns P > 0.05 vs. TBI group; # P < 0.05 and ## P < 0.01 vs. vehicle-treated group.

    Journal: American Journal of Translational Research

    Article Title: Mitochondrial-targeted antioxidant MitoQ provides neuroprotection and reduces neuronal apoptosis in experimental traumatic brain injury possibly via the Nrf2-ARE pathway

    doi:

    Figure Lengend Snippet: MitoQ accelerated translocation of Nrf2 from cytoplasm to nucleus. A-C. The levels of nuclear Nrf2, cytoplasmic Nrf2, and total Nrf2 were measured by western blot. D, E. The ratios of nuclear Nrf2 and cytoplasmic Nrf2. F. Representative immunofluorescence staining of Nrf2 after MitoQ treatment in mice with TBI. Double immunofluorescence analysis was performed with Nrf2 antibodies (red), NeuN (green), and DAPI (blue). The merged immunofluorescent images with NeuN, Nrf2 and DAPI represented for Nrf2 translocation from the cytoplasm to the nucleus. The white arrows indicate expressions and overlaps of NeuN, Nrf2 and DAPI. Scale bar =50 μm; Data are presented as mean ± SEM (n=6). * P < 0.05, ** P < 0.01 and *** P < 0.001 vs. sham group; ns P > 0.05 vs. TBI group; # P < 0.05 and ## P < 0.01 vs. vehicle-treated group.

    Article Snippet: F. Representative immunofluorescence staining of Nrf2 after MitoQ treatment in mice with TBI.

    Techniques: Translocation Assay, Western Blot, Immunofluorescence, Staining

    MitoQ upregulated the expression of Nrf2 downstream proteins in mice after TBI. A-D. The expression of HO-1 and Nqo1 was elevated following TBI. Moreover, MitoQ further upregulated their expression in the ipsilateral cortex after treatment with MitoQ (n=6). E, F. The mRNA expression of HO-1 and Nqo1 was enhanced after TBI and was further increased with MitoQ administration (n=3). Relative intensity means Nqo1 or HO-1/β-actin. Data are presented as mean ± SEM. ** P < 0.01, and *** P < 0.001 vs. sham group; ns P > 0.05 vs. TBI group; ## P < 0.01 and ### P < 0.001 vs. vehicle-treated group.

    Journal: American Journal of Translational Research

    Article Title: Mitochondrial-targeted antioxidant MitoQ provides neuroprotection and reduces neuronal apoptosis in experimental traumatic brain injury possibly via the Nrf2-ARE pathway

    doi:

    Figure Lengend Snippet: MitoQ upregulated the expression of Nrf2 downstream proteins in mice after TBI. A-D. The expression of HO-1 and Nqo1 was elevated following TBI. Moreover, MitoQ further upregulated their expression in the ipsilateral cortex after treatment with MitoQ (n=6). E, F. The mRNA expression of HO-1 and Nqo1 was enhanced after TBI and was further increased with MitoQ administration (n=3). Relative intensity means Nqo1 or HO-1/β-actin. Data are presented as mean ± SEM. ** P < 0.01, and *** P < 0.001 vs. sham group; ns P > 0.05 vs. TBI group; ## P < 0.01 and ### P < 0.001 vs. vehicle-treated group.

    Article Snippet: F. Representative immunofluorescence staining of Nrf2 after MitoQ treatment in mice with TBI.

    Techniques: Expressing